Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Saori Inaba
Institution:
Japanese Foundation For Cancer Research
Observed institution:
Japanese Foundation For Cancer Research
ORCID:
0009-0003-3945-9054
Observed ORCID:
0009-0003-3945-9054
OpenAlex ID:
A5103044144
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
2023
·
Mingjue Chen
, Tetsuo Mashima
, et al.
·
British Journal of Cancer
·
14
PDF
Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
·
Cancer Research Communications
·
11
Intratumor transforming growth factor-β signaling with extracellular matrix-related gene regulation marks chemotherapy-resistant gastric cancer
2024
·
Ayane Nakamura
, Tetsuo Mashima
, et al.
·
Biochemical and Biophysical Research Communications
·
5
PDF
Abstract 3052: RK-582, a tankyrase inhibitor, attacks Wnt-driven colorectal cancer cells with short-type APC mutations and high β-catenin expression
2026
·
Hiroyuki Seimiya
, Mingjue Chen
, et al.
·
Cancer Research
Supplementary Table S3 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Materials and Methods from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S1 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S4 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 3 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 5 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S2 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 1 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S6 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S5 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Table S2 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Figure S3 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Supplementary Tables S1 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 5 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Data from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 6 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 2 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 4 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Data from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
FIGURE 4 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer
2024
·
Jin Lee
, Tetsuo Mashima
, et al.
Show more works
View as search
Works count:
24
Citation count:
30
H-index:
3
I10-index:
2
Year
Topic
Type